Compare SHIM & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHIM | RCEL |
|---|---|---|
| Founded | 1990 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.5M | 102.5M |
| IPO Year | 2023 | N/A |
| Metric | SHIM | RCEL |
|---|---|---|
| Price | $3.14 | $3.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $11.75 |
| AVG Volume (30 Days) | 37.3K | ★ 200.7K |
| Earning Date | 11-13-2025 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $495,984,000.00 | $72,401,000.00 |
| Revenue This Year | $6.91 | $13.12 |
| Revenue Next Year | $13.03 | $27.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 20.59 |
| 52 Week Low | $1.30 | $3.25 |
| 52 Week High | $3.50 | $14.16 |
| Indicator | SHIM | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 68.37 | 44.70 |
| Support Level | $2.60 | $3.37 |
| Resistance Level | $2.98 | $3.71 |
| Average True Range (ATR) | 0.20 | 0.19 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 78.41 | 47.83 |
Shimmick Corp is a provider of water and other critical infrastructure solutions nationwide. It selectively focuses on the following types of infrastructure projects: Water Treatment, Water Resources, and Other Critical Infrastructure. In water treatment projects the company expands, rehabilitates, upgrades, builds and rebuilds water and wastewater treatment infrastructure, including desalination plants. In water resources projects company builds, expands, and improves water storage and conveyance, dams, levees, flood control systems, pump stations, and coastal protection. In Other Critical Infrastructure projects, It builds, retrofits, expands, rehabilitates, operates, and maintains its nation's critical infrastructure, including mass transit, bridges, and military infrastructure.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.